80 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00773 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 11.1 µMo/L |
| dbacp00774 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 4.3 µMo/L |
| dbacp00775 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5 µMo/L |
| dbacp00776 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 6.4 µMo/L |
| dbacp00777 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 7.5 µMo/L |
| dbacp00778 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.4 µMo/L |
| dbacp00779 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 5.2 µMo/L |
| dbacp00780 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3.8 µMo/L |
| dbacp00781 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.7 µMo/L |
| dbacp00782 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 8.7 µMo/L |
| dbacp00783 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 6.2 µMo/L |
| dbacp00784 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 4.3 µMo/L |
| dbacp00785 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 6.4 µMo/L |
| dbacp00786 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.1 µMo/L |
| dbacp00787 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 4.4 µMo/L |
| dbacp00788 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2 µMo/L |
| dbacp00789 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.2 µMo/L |
| dbacp00790 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 7.2 µMo/L |
| dbacp00791 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.7 µMo/L |
| dbacp00792 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 3.5 µMo/L |
| dbacp00793 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 5.5 µMo/L |
| dbacp00794 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 2.7 µMo/L |
| dbacp00795 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 4.6 µMo/L |
| dbacp00796 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.2 µMo/L |
| dbacp00797 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 8.7 µMo/L |
| dbacp00798 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 6.5 µMo/L |
| dbacp00799 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 5.1 µMo/L |
| dbacp00800 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 5 µMo/L |
| dbacp00801 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 9.8 µMo/L |
| dbacp00802 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 2.9 µMo/L |
| dbacp00803 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 7.8 µMo/L |
| dbacp00804 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4.3 µMo/L |
| dbacp03570 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : > 83.6 µMo/L |
| dbacp03571 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03572 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 83.6 µMo/L |
| dbacp03573 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : > 83.6 µMo/L |
| dbacp03574 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : > 83.6 µMo/L |
| dbacp03575 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 16.4 µMo/L |
| dbacp03576 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03577 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : > 83.6 µMo/L |
| dbacp03578 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : > 83.6 µMo/L |
| dbacp03579 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03580 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : > 83.6 µMo/L |
| dbacp03581 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : > 83.6 µMo/L |
| dbacp03582 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : > 83.6 µMo/L |
| dbacp03583 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 37.7 µMo/L |
| dbacp03584 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03585 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : >83.6 µMo/L |
| dbacp03589 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 71 µMo/L |
| dbacp03590 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 59.8 µMo/L |
| dbacp03591 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 70.8 µMo/L |
| dbacp03592 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03593 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : >83.6 µMo/L |
| dbacp03594 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 15.6 µMo/L |
| dbacp03595 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 63.5 µMo/L |
| dbacp03596 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 64.7 µMo/L |
| dbacp03613 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 53 µMo/L |
| dbacp03614 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 58.7 µMo/L |
| dbacp03615 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 62.3 µMo/L |
| dbacp03616 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03617 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : >83.6 µMo/L |
| dbacp03618 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 14 µMo/L |
| dbacp03619 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 62.5 µMo/L |
| dbacp03620 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 58.6 µMo/L |
| dbacp03621 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : >83.6 µMo/L |
| dbacp03622 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03623 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : >83.6 µMo/L |
| dbacp03624 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : >83.6 µMo/L |
| dbacp03625 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : >83.6 µMo/L |
| dbacp03626 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : >83.6 µMo/L |
| dbacp03627 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03628 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : >83.6 µMo/L |
| dbacp05021 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 33 µMo/L |
| dbacp05022 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 17.8 µMo/L |
| dbacp05023 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 15.8 µMo/L |
| dbacp05024 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 11.1 µMo/L |
| dbacp05025 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 25.2 µMo/L |
| dbacp05026 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.7 µMo/L |
| dbacp05027 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 11.5 µMo/L |
| dbacp05028 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 10.4 µMo/L |